In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GPC Looks to Nasdaq for the Best of Both Worlds

Executive Summary

A late-June listing may help Germany's GPC Biotech AG attract investor interest and it certainly reinforces the firm's increasing Americanization. Yet the performance of lead candidate satraplatin remains the strongest determinant of GPC's valuation and near-term success.

You may also be interested in...



German Biotech: Coalescing around the Haves

Positive signs are coming out of German biotech for the first time in years. Scientific output remains strong. The subsector boasts its first profitable pharmaceutical-oriented company; several on- or near-market products, and even a nascent IPO market. The fact that dozens of companies are expected to go bust this year is another sign of the industry's maturation. The long-awaited consolidation predicted in the wake of the Neuer Markt demise is seemingly finally happening. The have-nots are finally beginning to cluster around the haves.

German Biotech: Coalescing around the Haves

Positive signs are coming out of German biotech for the first time in years. Scientific output remains strong. The subsector boasts its first profitable pharmaceutical-oriented company; several on- or near-market products, and even a nascent IPO market. The fact that dozens of companies are expected to go bust this year is another sign of the industry's maturation. The long-awaited consolidation predicted in the wake of the Neuer Markt demise is seemingly finally happening. The have-nots are finally beginning to cluster around the haves.

The US: To Go, or Not to Go?

Whether or not European biotechs should establish operations in the US may seem like a no brainer: it's the biggest drugs market, with more potential partners, better funding, more promising exits for investors and a more experienced management pool than Europe. But getting there-and getting noticed-isn't easy. And since most executives agree that going to the US half-heartedly isn't worthwhile, Europe's biotechs need to think hard about when and whether they're ready to go. For a minority, setting up in the US may not be the right solution-for now.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV002406

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel